FDA Approves Rapiblyk for Pediatric SVT Patients in U.S.
April 27, 2026
WILMINGTON, DE — The U.S. Food and Drug Administration recently approved RAPIBLYK® (landiolol) for pediatric patients from birth to under 18 years old with supraventricular tachycardia, expanding its use beyond ...
Source: mychesco